Adverse Events of the Use of SGLT2 Inhibitors in Patients with Heart Failure: A Systematic Review and Meta-analysis

Mariana Feldner de Britto

Post-Graduate Program of Health Sciences, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.

Ana Luiza Miranda de Oliveira

Post-Graduate Program of Health Sciences, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.

Ricardo Simões

Department of Medicine, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.

Nathalia Sernizon Guimarães

Department of Nutrition, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Janaine Cunha Polese

Department of Physiotherapy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Alessandra Hubner de Souza *

Department of Medicine, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil and Department of Post-Graduation in Health Sciences, Faculdade Ciências Médicas de Minas Gerais, Brazil.

*Author to whom correspondence should be addressed.


Abstract

Background: Sodium-glucose cotransporter 2 (iSGLT2) inhibitors are a class of medications used in the treatment of Heart Failure (HF) to prevent the development and worsening of the disease. Despite the benefits reported in the literature, it is essential to investigate its adverse effects.

Objective: To evaluate the occurrence of hypotension, volume depletion and acute kidney injury in patients with HF with reduced (HFrEF) and preserved (HFpEF) ejection fraction using iSGLT2.

Methodology: Systematic review and meta-analysis previously registered in PROSPERO (CRD42022365684) and carried out in the PubMed, EBSCO and LILACS databases. The risk of bias analysis was performed using the Cochrane risk-of-bias tool for randomized trials. RevMan 3.4.1 was used to perform the data meta-analysis.

Results: Of the 9,474 studies found, ten were included in the review. A risk of hypotension was observed in patients with HF using iSGLT2 (RR: 1.15; 95% CI 1.01 – 1.30; p=0.03; I2= 0%), but there was no risk statistically significant occurrence of volume depletion and acute kidney injury (RR: 1.12; 95% CI 0.95 – 1.33; p=0.17; I2= 0%; RR: 0.85; 95% CI 0 .69 – 1.06; p=0.14;I2= 16%).

Conclusion: In therapy with iSGLT2, an increased risk of adverse events of hypotension was observed, but no increased risk of volume depletion and acute kidney injury was observed. Despite the 15% reduction in relative risk in the outcome of acute kidney injury, the results suggest a renal benefit.

Keywords: Sodium-glucose transporter 2 inhibitors, heart failure, hypotension, systematic review


How to Cite

Britto , Mariana Feldner de, Ana Luiza Miranda de Oliveira, Ricardo Simões, Nathalia Sernizon Guimarães, Janaine Cunha Polese, and Alessandra Hubner de Souza. 2024. “Adverse Events of the Use of SGLT2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-Analysis”. Journal of Advances in Medicine and Medical Research 36 (7):65-76. https://doi.org/10.9734/jammr/2024/v36i75486.

Downloads

Download data is not yet available.

References

Mesquita ET, Jorge AJL, Rabelo LM, Souza Jr. CV. Understanding hospitalization in patients with heart failure. International Journal of Cardiovascular Sciences. 2016.

Carlos A, Sousa S, Felice A, Issa C, Ramos Nascimento B, Filho H, et al. Atualização de tópicos emergentes da diretriz brasileira de insuficiência cardíaca 2021. Arq. Bras. Cardiol. 2021;116(6):1174-1212.

Alessia Buglioni, Burnett JC. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators. Clin Chim Acta; 2015.

Zeng Q, Zhou Q, Liu W, Wang Y, Xu X, Xu D. Mechanisms and perspectives of sodium-glucose co-transporter 2 inhibitors in heart failure. Front Cardiovasc Med. 202;8.

Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus; 2023.

Lai L, Zhang Y, Li X, Zhang Y, Zhang M, zhao. Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure-may raise creatinine levels in patients: a meta-analysis [Internet]. Authorea; 2022.

Soloveva A, Fedorova D, Villevalde S, Zvartau N, Mareev Y, Sitnikova M, et al. Addressing orthostatic hypotension in heart failure: pathophysiology, clinical implications and perspectives. J Cardiovasc Transl Res. 2020;13(4):549–69.

Cautela J, Tartiere J, Cohen-Solal A, Bellemain‐Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail. 2020;22(8):1357–65.

Min K-D, Asakura M. Evaluation of volume depletion in patients with heart failure using intrathoracic impedance monitoring. Circ J. 2012;76(11):2538–9.

Lu H, Meyer P, Hullin R. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? Swiss Med Wkly; 2020.

Holgado JL, Lopez C, Fernandez A, Sauri I, Uso R, Trillo JL, et al. Acute kidney injury in heart failure: a population study. ESC Heart Fail. 2020;7(2):415–22.

Boorsma EM, ter Maaten JM, Voors AA, van Veldhuisen DJ. Renal Compression in Heart Failure. JACC Heart Fail. 2022;10(3):175–83.

Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2021;20(1):83.

Deshpande R, Patel R, Manjari Regmi, Salih M, Kropp R, Basma Al-bast, et al. Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2023;12(2).

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis. ESC Heart Fail. 2020;7(6):3298–309.

Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17(5):147916412095362.

Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1): e022577.

Menne J, Dumann E, Haller H, Schmidt BMW. acute kidney injury and adverse renal events in patients receiving sglt2-inhibitors: a systematic review and meta-analysis. Taal MW, editor. PLoS Med. 2019;16(12):e1002983

Vukadinović D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, et al. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail; 2022.

Wahinya M, Khan Z. Sodium-Glucose cotransporter-2 (SGLT2) inhibitor therapy for the primary and secondary prevention of heart failure in patients with and without type 2 diabetes mellitus: a systematic review. Cureus; 2023.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372(71).

Helena A, Luiza A, Carolina Gassen Fritsch, Zouch J, Ferreira PH, Janaine Cunha Polese. Usefulness of machine learning softwares to screen titles of systematic reviews: a methodological study. Syst Rev. 2023;12(1).

Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC de, Rassi S, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq. Bras. Cardiol. 2018;111(3).

Bozkurt B, Coats A, Tsutsui H. A Report of the Heart Failure Society of America, Heart failure association of the european society of cardiology, japanese heart failure society and writing committee of the universal definition of heart failure consensus conference. Eur J Heart Fail. 2021;23(3).

Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107(13).

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18).

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–60.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16).

Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation; 2020.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21).

Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of sglt2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the recede-chf trial. Circulation; 2020.

Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the define-hf trial. Circulation; 2019.

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1–7.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med. 2017;377(7):644–57.

Omar M, Jensen J, Frederiksen P, Kistorp C, Lars Videbæk, Mikael Kjær Poulsen, et al. Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2020;76(23):2740–51.

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15).

Solomon SD, McMurray JJV, Claggett B, de Boer RA, De Mets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med; 2022.

Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci (Lond). 2018;132(1):1329–39.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis. Diabetes Obes Metab. 2019;21(5):1237–50.

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis. ESC Heart Fail. 2020;7(6):3298–309.